Biogen | BIIB - Current Assets


Biogen reported $8.97B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Bayer EUR 32.91B 30M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
United Therapeutics USD 3.7B 208.5M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025